The Depo-Provera lawsuit is one of the largest pharmaceutical mass tort cases heading into 2026. Thousands of women who received the popular birth control injection and later developed meningioma brain tumors are now pursuing legal claims against Pfizer and its subsidiaries.
This litigation centers on a serious allegation. The manufacturers knew about the brain tumor risk and failed to warn patients or doctors. A 2024 study published in the BMJ found that prolonged Depo-Provera use was associated with a significantly increased risk of intracranial meningioma.
If you used Depo-Provera and were diagnosed with a meningioma, you could be entitled to compensation. This article covers everything you need to know: current case status, projected settlement amounts, who qualifies, how to file, critical deadlines, and what to expect throughout 2026.
Here’s one number worth remembering. Over 70,000 potential claimants have been identified so far, and the case count keeps growing.
Depo-Provera Lawsuit 2026: Where Things Stand Right Now
The Depo-Provera lawsuit in 2026 is in active litigation within a federal multidistrict litigation (MDL) proceeding. Cases have been consolidated in the U.S. District Court for the Northern District of Alabama under MDL No. 3127, with Judge R. Austin Huffaker Jr. presiding.
By early 2026, the litigation has moved past the initial consolidation phase. Discovery is underway, meaning both sides are exchanging documents, expert reports, and internal company communications. This is the phase where the real evidence surfaces.
Bellwether trial selections are expected to take shape throughout 2026. These are test cases chosen to represent the broader pool of claims. Their outcomes will heavily influence any eventual settlement negotiations.
Pfizer continues to deny liability, arguing that Depo-Provera’s labeling was adequate. Plaintiffs’ attorneys disagree and point to internal documents suggesting the company had early knowledge of the meningioma risk.
| 2026 Case Snapshot | Details |
|---|---|
| MDL Number | 3127 |
| Court | U.S. District Court, Northern District of Alabama |
| Judge | R. Austin Huffaker Jr. |
| Phase | Discovery and bellwether selection |
| Defendant | Pfizer Inc., Pharmacia & Upjohn |
| Number of Pending Cases | Thousands and growing |
The pace of this litigation in 2026 will set the stage for whether a global settlement happens in 2027 or whether individual trials begin first.
Is There a Depo-Provera Class Action Lawsuit?
The Depo-Provera litigation is technically not a class action lawsuit. It is a mass tort consolidated as a multidistrict litigation, which works differently.
In a class action, one or a few plaintiffs represent an entire group. Everyone in the class gets the same outcome. Mass tort cases are different because each plaintiff files an individual claim with their own unique medical history, usage timeline, and injury severity.
This distinction matters for payouts. In a mass tort, your compensation depends on your specific situation. A woman who had surgery to remove a large meningioma will likely receive more than someone with a smaller, monitored tumor.
The MDL structure simply groups all federal cases in one court for pretrial proceedings. This keeps things efficient. Each case still maintains its individual identity.
- Class action: one outcome for all members
- Mass tort (MDL): individual outcomes based on each person’s case
- Current structure: MDL No. 3127, Northern District of Alabama
Some state court cases are proceeding separately outside the federal MDL. That means the litigation is happening on two tracks simultaneously.
People often search for “Depo-Provera class action lawsuit” because that’s the most familiar term. But understanding that this is a mass tort helps set realistic expectations about timelines and payouts.
The Depo-Provera Meningioma Lawsuit Explained
The Depo-Provera meningioma lawsuit alleges that the synthetic progestin in the birth control shot, medroxyprogesterone acetate, causes the growth of meningioma brain tumors. These are typically benign tumors that form in the membranes surrounding the brain and spinal cord.
“Benign” sounds harmless, but these tumors are anything but. They can cause severe headaches, vision problems, seizures, hearing loss, memory issues, and personality changes. Many require surgical removal, and some patients face lifelong neurological damage.
The scientific evidence linking Depo-Provera to meningioma has strengthened over time. A large-scale 2024 BMJ study from French researchers found that women who used medroxyprogesterone acetate for more than one year had a significantly elevated risk of developing intracranial meningioma.
France actually pulled the drug from its market based on this data. The European Medicines Agency reviewed the findings and issued warnings. In the United States, however, Depo-Provera remained available without updated warning labels for years.
Plaintiffs argue that Pfizer and its predecessor companies knew about this risk and chose not to warn patients or healthcare providers. This is the core legal theory: failure to warn.
| Key Allegation | Detail |
|---|---|
| Drug | Depo-Provera (medroxyprogesterone acetate 150mg) |
| Condition | Intracranial meningioma |
| Key Study | 2024 BMJ study (French cohort) |
| Legal Theory | Failure to warn, product liability |
| Country That Banned It | France |
Key Takeaway: The Depo-Provera lawsuit is a mass tort (not a class action) consolidated in an Alabama federal court, centered on the drug’s link to meningioma brain tumors and the manufacturer’s failure to warn users.
Depo-Provera Settlement Amounts: What to Expect
Depo-Provera settlement amounts have not been finalized as of 2026 because no global settlement has been reached yet. However, legal analysts and mass tort attorneys have provided projected ranges based on injury severity tiers.
Individual settlement values in mass tort pharmaceutical cases depend on several factors. These include the severity of the brain tumor, whether surgery was required, the duration of Depo-Provera use, the claimant’s age at diagnosis, and the extent of lasting medical complications.
Based on comparable pharmaceutical mass tort settlements and early case evaluations, projected payouts fall into a tiered structure.
| Injury Tier | Description | Estimated Payout Range |
|---|---|---|
| Tier 1 (Severe) | Surgical removal, permanent neurological damage, multiple tumors | $300,000 to $750,000+ |
| Tier 2 (Moderate) | Surgical removal, partial recovery, some lasting effects | $150,000 to $300,000 |
| Tier 3 (Lower) | Small meningioma, monitored without surgery, minor symptoms | $50,000 to $150,000 |
These numbers are projections, not guarantees. Actual settlement amounts will depend on the strength of evidence, the outcome of bellwether trials, and how aggressively Pfizer negotiates.
Cases with clear medical documentation, long usage history, and severe injuries will command higher values. Weaker cases with limited records or shorter usage periods may settle for less or face challenges proving causation.
How Much Is the Depo-Provera Lawsuit Payout?
The Depo-Provera lawsuit payout per claim is projected to range from $50,000 to $750,000 or more, depending on individual circumstances. No payouts have been distributed yet because the litigation is still in pretrial stages.
To understand potential payouts, it helps to look at similar pharmaceutical cases. The Zantac MDL, the talcum powder litigation, and the Essure lawsuits all involved product liability claims with tiered settlement structures. Those cases show that severe injury claims can reach six and even seven figures.
Attorney fees typically take 33% to 40% of the gross settlement amount. Case costs, including expert witness fees and medical record retrieval, are deducted separately. So a $300,000 gross payout might net you around $170,000 to $190,000 after fees and costs.
- Gross payout depends on injury severity and evidence strength
- Attorney contingency fees: typically 33% to 40%
- Case costs deducted from your share
- Net payout is roughly 55% to 65% of the gross figure
Some attorneys offer free case evaluations and work on contingency. That means you pay nothing upfront and only owe fees if you win or settle. This makes legal representation accessible even if you cannot afford hourly attorney rates.
Depo-Provera Settlement Payout Per Person
The Depo-Provera settlement payout per person will vary significantly because each claim is evaluated individually. This is not a flat-rate settlement where everyone gets the same check.
Mass tort settlements use point-based systems to calculate individual payouts. Points are assigned based on specific criteria. The more points your case accumulates, the higher your settlement value.
| Point Factor | What It Measures | Impact on Payout |
|---|---|---|
| Duration of use | How many years you received injections | Longer use = higher value |
| Tumor size | Diameter of meningioma at diagnosis | Larger tumors = higher value |
| Surgery required | Whether craniotomy or other surgery was performed | Surgery = significantly higher |
| Neurological damage | Lasting cognitive, vision, or motor impairments | Permanent damage = highest tier |
| Age at diagnosis | Younger patients face more years of impact | Younger age = higher value |
| Number of tumors | Single vs. multiple meningiomas | Multiple = higher value |
A woman who used Depo-Provera for eight years, had a large meningioma surgically removed, and now lives with permanent vision loss would be in the highest settlement tier. Someone who used it for two years and has a small, monitored tumor would receive substantially less.
The per-person amount also depends on the total settlement fund. If Pfizer agrees to a $5 billion global settlement and 50,000 claimants qualify, the math is different than if only 20,000 qualify.
Key Takeaway: Settlement payouts will be individualized, not uniform, with projected ranges from $50,000 to $750,000 or more based on a points system that weighs injury severity, duration of drug use, and lasting medical harm.
Depo-Provera Lawsuit Eligibility Requirements
To be eligible for the Depo-Provera lawsuit, you generally must have received at least one Depo-Provera injection and been diagnosed with a meningioma brain tumor. Those are the two baseline requirements.
Beyond those basics, attorneys evaluate several additional factors when determining whether your case is strong enough to pursue. Not every person who used Depo-Provera and developed a meningioma will automatically have a viable claim.
Core eligibility criteria include:
- Received one or more Depo-Provera injections
- Diagnosed with intracranial meningioma (confirmed by MRI or CT scan)
- Meningioma diagnosis came after starting Depo-Provera use
- Able to provide medical records showing both drug use and diagnosis
- Claim falls within the applicable statute of limitations
Stronger cases involve longer usage periods, typically more than one year of injections. The 2024 BMJ study specifically identified elevated risk among women who used the drug for prolonged periods.
You do not need to have had surgery to qualify. Women whose meningiomas are being monitored through regular imaging may still file. However, surgical cases tend to have higher settlement values because the injury is more clearly documented and severe.
Who Qualifies for the Depo-Provera Lawsuit?
Women who used Depo-Provera and were later diagnosed with a meningioma brain tumor are the primary group that qualifies. Family members of deceased users may also have standing to file wrongful death claims.
Think of it like a Venn diagram. You need to be in the overlap of two circles: Depo-Provera users AND meningioma patients. If you only fall in one circle, you probably don’t have a claim.
Here are the groups that generally qualify:
- Women who received Depo-Provera injections at any point
- Women diagnosed with meningioma after beginning Depo-Provera use
- Estate representatives of women who died from meningioma complications
- Women who underwent surgery for meningioma removal
- Women currently under active surveillance for meningioma
Some people wonder whether men can file. While men rarely receive Depo-Provera, the drug is occasionally prescribed off-label for certain conditions. A man who used medroxyprogesterone acetate and developed meningioma could theoretically qualify, though these cases would be rare.
Geographic eligibility matters too. Most claims in the federal MDL are from U.S. residents, but some international claimants may have options depending on where they received treatment and which court has jurisdiction.
| Qualifying Factor | Required? |
|---|---|
| Used Depo-Provera | Yes |
| Diagnosed with meningioma | Yes |
| Diagnosis came after drug use | Yes |
| Surgery required | No, but strengthens claim |
| U.S. resident | Preferred, but not always required |
| Minimum usage period | Not strictly, but 1+ years preferred |
Depo-Provera Brain Tumor Lawsuit Details
The Depo-Provera brain tumor lawsuit specifically targets intracranial meningioma, a tumor that grows in the meninges, the protective layers surrounding the brain. These tumors are usually slow-growing but can cause devastating symptoms.
Meningiomas account for about 40% of all primary brain tumors. While they are typically classified as benign, their location inside the skull means they can press against brain tissue and cause serious problems. Size and location determine severity.
Symptoms that Depo-Provera meningioma plaintiffs commonly report include:
- Chronic headaches that worsen over time
- Blurred or double vision
- Hearing loss in one or both ears
- Seizures
- Weakness in arms or legs
- Memory loss and cognitive difficulties
- Personality or behavioral changes
The diagnosis process usually involves an MRI or CT scan. Many women discover their meningioma incidentally, during imaging for an unrelated issue. Others seek medical attention after experiencing neurological symptoms.
Treatment ranges from watchful waiting (active surveillance with regular MRI scans) to surgical removal (craniotomy). In some cases, radiation therapy is used when surgery is too risky or the tumor returns after removal.
The connection between progesterone-based drugs and meningioma has been studied for over a decade. Meningiomas have high concentrations of progesterone receptors, which means they can be stimulated to grow by progestin-based medications like Depo-Provera.
Key Takeaway: The lawsuit specifically targets meningioma brain tumors linked to Depo-Provera’s active ingredient, and even “benign” meningiomas can cause severe neurological symptoms requiring surgery or lifelong monitoring.
Depo-Provera Side Effects That Led to Lawsuits
The side effects driving the Depo-Provera lawsuits are centered on meningioma brain tumors, not the commonly known side effects like weight gain or irregular bleeding. This is specifically about a life-threatening condition the manufacturer allegedly failed to disclose.
Depo-Provera has a long list of acknowledged side effects. Most are well-documented on the drug’s label. These include weight gain, bone density loss, mood changes, decreased libido, and menstrual irregularities. Doctors typically discuss these with patients before prescribing.
What was not adequately disclosed, according to the lawsuits, is the risk of developing brain tumors. The difference between a known side effect and a hidden one is the foundation of the failure-to-warn claim.
| Known (Labeled) Side Effects | Alleged Hidden Risk |
|---|---|
| Weight gain | Meningioma brain tumors |
| Bone density loss | Intracranial tumor growth |
| Irregular periods | Need for brain surgery |
| Mood changes | Permanent neurological damage |
| Headaches | Seizures from tumor pressure |
The argument is straightforward. If women and their doctors had known about the brain tumor risk, many would have chosen a different contraceptive method. That lost choice is at the heart of every claim.
Pfizer’s defense is expected to argue that the known headache side effect was disclosed and that the label was adequate under FDA standards. Plaintiffs counter that a headache warning is worlds apart from a brain tumor warning.
How to File a Depo-Provera Lawsuit
To file a Depo-Provera lawsuit, you start by contacting a mass tort attorney who is accepting meningioma cases. Most attorneys offer free initial consultations and work on a contingency fee basis.
The filing process involves several steps, and your attorney handles most of the heavy lifting. Here’s what the process typically looks like:
Step 1: Free Case Evaluation
You speak with an attorney or legal team. They review your Depo-Provera usage history and meningioma diagnosis to determine if you have a viable claim.
Step 2: Gather Medical Records
Your legal team collects pharmacy records showing Depo-Provera injections and medical records documenting your meningioma diagnosis, imaging, and any treatments.
Step 3: File the Complaint
Your attorney files a formal complaint in either federal court (joining the MDL) or state court, depending on strategy and jurisdiction.
Step 4: Discovery and Case Building
Your legal team works with medical experts to establish the causal link between your Depo-Provera use and your meningioma.
Step 5: Settlement Negotiation or Trial
Your case either resolves through a negotiated settlement or proceeds to trial.
- You pay nothing upfront with contingency fee arrangements
- The entire process from filing to resolution can take 2 to 5 years
- You do not need to appear in court during pretrial phases
- Most communication happens through your attorney
Do not wait to start this process. Statutes of limitations vary by state, and delays in filing can jeopardize your claim.
What Evidence Do You Need for a Depo-Provera Lawsuit?
The evidence you need for a Depo-Provera lawsuit includes medical records confirming your meningioma diagnosis and pharmacy or clinic records proving you received Depo-Provera injections. These two categories form the backbone of your claim.
Think of it as building a bridge. One side is proof that you took the drug. The other side is proof that you developed the tumor. Your attorney’s job is to connect those two sides with medical expert testimony.
Essential evidence includes:
- Pharmacy records: Dates and locations of Depo-Provera injections
- Medical charts: Doctor visit notes mentioning Depo-Provera administration
- MRI or CT scans: Imaging confirming meningioma diagnosis
- Pathology reports: Biopsy or surgical pathology results if available
- Surgical records: Operative reports if tumor was removed
- Neurologist notes: Documentation of symptoms and treatment plans
| Evidence Type | Where to Get It | How Important |
|---|---|---|
| Pharmacy dispensing records | Your pharmacy or insurance company | Critical |
| Injection clinic records | Doctor’s office or women’s health clinic | Critical |
| Brain MRI/CT reports | Hospital radiology department | Critical |
| Surgical records | Hospital medical records department | Very important (if applicable) |
| Insurance claim history | Your health insurance provider | Helpful |
| Personal timeline notes | Your own records or calendar | Supportive |
If you can’t find your pharmacy records from years ago, don’t panic. Your attorney can subpoena records from pharmacies, insurance companies, and medical providers. Electronic health records go back decades in many systems.
Key Takeaway: Strong evidence combines pharmacy records proving Depo-Provera use, brain imaging confirming meningioma, and medical records showing the timeline; your attorney can help retrieve records you can’t easily access.
Depo-Provera MDL Update for 2026
The Depo-Provera MDL (multidistrict litigation) in 2026 is progressing through the discovery phase, with bellwether trial selections expected to be a major focus. MDL No. 3127 continues to grow as new cases are filed and transferred to the Northern District of Alabama.
The Judicial Panel on Multidistrict Litigation (JPML) created this MDL in 2024, consolidating federal Depo-Provera meningioma cases under one roof. Since then, the case count has climbed steadily.
Key MDL developments expected in 2026 include:
- Completion of initial discovery and document production
- Selection of bellwether cases from the plaintiff pool
- Daubert hearings on expert witness qualifications
- Potential appointment of a special master for case management
- Possible early settlement discussions
Bellwether trials are the most important milestone to watch. These are a small number of representative cases that go to trial first. If plaintiffs win bellwether verdicts, it puts pressure on Pfizer to settle. If Pfizer wins, it weakens the plaintiffs’ negotiating position.
The MDL process can feel slow, but it’s designed to be efficient. Without consolidation, thousands of nearly identical cases would clog courts across the country. The MDL structure saves time and resources for both sides.
Judge Huffaker’s management of the docket will determine how quickly things move. Some MDL judges push for aggressive timelines. Others let the process unfold more gradually. Early indications suggest a moderately paced schedule.
Depo-Provera Lawsuit Timeline: Key Dates
The Depo-Provera lawsuit timeline stretches from the first individual filings through the MDL consolidation and into the bellwether trial phase expected in late 2026 or 2027. Here is the chronology of major events.
| Date | Milestone |
|---|---|
| 2024 (early) | BMJ publishes major study linking Depo-Provera to meningioma |
| 2024 (mid) | First wave of individual lawsuits filed in federal courts |
| 2024 (late) | JPML consolidates cases into MDL No. 3127 in Alabama |
| 2025 | Discovery phase begins; initial case management orders issued |
| 2026 (Q1-Q2) | Document production and expert discovery ongoing |
| 2026 (Q3-Q4) | Bellwether case selection and Daubert hearings expected |
| 2027 (projected) | First bellwether trials or global settlement negotiations |
| 2027-2028 (projected) | Settlement distribution or continued trials |
Each of these phases can shift depending on court schedules, motions, and negotiation progress. Mass tort timelines are notoriously unpredictable.
If you’re thinking about filing, the timeline matters because earlier filers have their cases further along in the process. Later filers join the MDL but may face longer waits if settlement distributions are phased.
The 2024 BMJ study was a turning point. Before that research was published, scattered lawsuits existed but lacked the scientific support needed to sustain a mass litigation effort. That study gave attorneys the evidence they needed to file thousands of claims.
Depo-Provera Lawsuit Statute of Limitations
The statute of limitations for a Depo-Provera lawsuit varies by state, typically ranging from 1 to 6 years from the date you discovered (or should have discovered) your meningioma was linked to the drug. This is called the “discovery rule.”
Understanding the discovery rule is essential. In most states, the clock doesn’t start ticking when you first receive Depo-Provera. It starts when you knew or reasonably should have known that the drug may have caused your meningioma.
Because the link between Depo-Provera and meningioma only became widely known through the 2024 BMJ study, many claimants may have a strong argument that the discovery clock started recently. This gives women who were diagnosed years ago a potential path to filing.
| State (examples) | Statute of Limitations | Discovery Rule |
|---|---|---|
| California | 2 years | Yes, from date of discovery |
| Texas | 2 years | Yes |
| Florida | 2 years (changed from 4 in 2024) | Yes |
| New York | 3 years | Yes |
| Illinois | 2 years | Yes |
| Pennsylvania | 2 years | Yes |
These are general guidelines. Each state has its own nuances, exceptions, and court interpretations. Some states apply a “statute of repose” that creates an absolute outer deadline regardless of when you discovered the injury.
Do not assume you have plenty of time. Even with the discovery rule working in your favor, filing sooner is always better than filing later. Delays can result in lost evidence, faded memories, and destroyed medical records.
Key Takeaway: Statutes of limitations vary by state but the discovery rule may protect women who only recently learned about the Depo-Provera and meningioma connection; filing sooner rather than later is always the safer move.
Depo-Provera Class Action Settlement: How It Works
A Depo-Provera class action settlement (more accurately, a mass tort global settlement) would work by creating a settlement fund that compensates individual claimants based on their injury severity and case strength. No such settlement has been finalized as of 2026.
Here’s how mass tort settlements typically unfold once both sides agree to negotiate:
Step 1: Settlement Framework
Attorneys for both sides agree on a total settlement amount and a point-based system for distributing funds.
Step 2: Claims Administration
A court-appointed settlement administrator reviews each claim. They verify eligibility, assign points, and calculate individual payouts.
Step 3: Claim Submission
Each claimant submits documentation including medical records, pharmacy records, and a claims form through their attorney.
Step 4: Review and Allocation
The administrator evaluates each claim, assigns a tier and point value, and determines the payout amount.
Step 5: Distribution
Checks are issued to claimants through their attorneys. Attorney fees and costs are deducted before you receive your share.
- The entire settlement process from agreement to payout can take 12 to 24 months
- Claimants do not need to negotiate individually
- Attorneys handle all paperwork and submissions
- You retain the right to reject a settlement and pursue trial instead
Some mass tort settlements include a “walkaway” provision. If fewer than a certain percentage of claimants accept the settlement terms, the defendant can withdraw the offer. This is designed to ensure finality.
Are Depo-Provera Lawsuit Settlements Taxable?
Most Depo-Provera lawsuit settlement proceeds for physical injury claims are not taxable under federal law. The IRS generally excludes compensation received for physical injuries or physical sickness from gross income under Section 104(a)(2) of the Internal Revenue Code.
This means the portion of your settlement that compensates you for your meningioma, surgery, medical bills, pain and suffering, and physical disability is typically tax-free. That’s the good news.
However, certain portions of a settlement may be taxable:
- Punitive damages: Always taxable as ordinary income
- Interest on the settlement: Taxable as interest income
- Emotional distress (without physical injury): May be taxable
- Lost wages component: May be subject to income and payroll taxes
| Settlement Component | Taxable? |
|---|---|
| Compensation for physical injury | No |
| Medical expense reimbursement | No |
| Pain and suffering (from physical injury) | No |
| Punitive damages | Yes |
| Interest on settlement | Yes |
| Lost wages | Possibly |
How your settlement is structured matters. Your attorney can work with a tax professional to allocate settlement proceeds in a way that maximizes the tax-free portion. This allocation should be addressed before you sign any settlement agreement.
State tax rules may differ from federal rules. Some states tax settlement proceeds that the IRS does not. Check your state’s specific rules or talk to a local tax professional.
Depo-Provera Settlement Funding Options
Depo-Provera settlement funding, sometimes called pre-settlement funding or lawsuit loans, provides cash advances to plaintiffs while they wait for their case to resolve. This can take years, and many claimants need financial help in the meantime.
Pre-settlement funding is not a traditional loan. You only repay it if you win or settle your case. If your case is dismissed or you lose at trial, you owe nothing. The funding company absorbs the risk.
How pre-settlement funding works:
- You apply with a funding company
- They review your case strength with your attorney
- If approved, you receive a cash advance (typically $500 to $100,000)
- Repayment comes from your settlement proceeds
- If you don’t win, you don’t repay
| Funding Detail | Typical Terms |
|---|---|
| Minimum advance | $500 to $1,000 |
| Maximum advance | $100,000+ (depends on case value) |
| Interest/fees | 15% to 60% annually (varies widely) |
| Repayment trigger | Only if you win or settle |
| Application timeline | 24 to 48 hours for approval |
There are trade-offs. Funding companies charge high fees and interest rates. A $10,000 advance could cost you $15,000 to $25,000 or more by the time your case resolves years later. That money comes directly out of your settlement.
Your attorney must typically approve the funding arrangement. Many attorneys advise caution and recommend exploring other financial options first, such as medical liens, payment plans with providers, or personal savings. Pre-settlement funding should be a last resort, not a first choice.
Key Takeaway: Pre-settlement funding can provide needed cash during the long wait for resolution, but high interest rates and fees mean you’ll receive less from your eventual settlement; treat it as a last resort.
Frequently Asked Questions
How much money can I get from a Depo-Provera lawsuit?
Projected individual payouts range from $50,000 to $750,000 or more, depending on injury severity.
Cases involving surgery, permanent neurological damage, and long drug usage periods command the highest values.
No payouts have been distributed yet because the litigation is still in pretrial stages.
What is the deadline to file a Depo-Provera lawsuit?
The deadline depends on your state’s statute of limitations, which typically ranges from 1 to 6 years from the date of discovery.
The discovery rule means the clock may have started recently for many women who only learned of the drug’s connection to meningioma through the 2024 BMJ study.
Filing sooner protects your rights and preserves evidence.
Can I still file a Depo-Provera lawsuit in 2026?
Yes, new cases are still being accepted into the MDL in 2026.
Attorneys are actively taking new Depo-Provera meningioma claims.
The sooner you file, the further along your case will be when settlements or trials begin.
Does Depo-Provera really cause brain tumors?
Scientific research strongly supports the link between Depo-Provera and meningioma brain tumors.
The 2024 BMJ study found a significantly elevated risk among women who used the drug for more than one year.
France banned the drug based on this evidence, and European regulators issued safety warnings.
How long will the Depo-Provera lawsuit take to settle?
Most legal experts project that settlements or initial trial verdicts could come in 2027 or 2028.
The litigation is currently in discovery, with bellwether trial selections expected in late 2026.
From settlement agreement to actual payout distribution, expect an additional 12 to 24 months.
The Depo-Provera lawsuit is moving forward, and 2026 is a critical year for building cases and preparing for trial. If you used the injection and were diagnosed with meningioma, now is the time to gather your medical records and pharmacy history.
Don’t wait for a settlement announcement to take action. Connect with a mass tort attorney, get your free case evaluation, and secure your place in the litigation.
The deadlines are real. The evidence window is open. Your claim is worth protecting.
